| abstract |
There are disclosed compounds of the formula <IMAGE> wherein <IMAGE> <IMAGE> n is 0-5; R2 is, independently, hydrogen, loweralkyl, loweralkoxy, trifluoromethyl or halo; <IMAGE> W represents a bond or <IMAGE> m is 1-15; R4 is hydrogen or loweralkyl; R5 is lower alkyl, monofluoroloweralkyl, difluoroloweralkyl, polyfluoroloweralkyl, perfluoroloweralkyl or <IMAGE> or a pharmaceutically acceptable salt thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and as antiinflammatory agents. |